GlassScriptPhysician profile
Kevin J Kempf
NPI 1003895020
$82,508.92
in general payments reported to CMS, 2019-2025
52 companies · $4,219 in 2025
The $4,219 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $11K · 2021: $3,065 · 2022: $11K · 2023: $3,327 · 2024: $3,744 · 2025: $4,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,156.74 |
| Education | $132.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18,318.77 | 2019-2025 | Benlysta, Nucala, Arexvy |
| Celgene Corporation | $17,570.28 | 2019 | |
| Amgen INC. | $13,573.82 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Ucb, INC. | $7,839.65 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $7,430.68 | 2019-2025 | |
| Horizon Therapeutics Plc | $4,346.29 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $1,766.65 | 2019-2025 | Tremfya, Simponi Aria, Acclarent Aera |
| Mallinckrodt Hospital Products INC. | $1,386.13 | 2020-2025 | Acthar |
| Lilly USA, LLC | $1,209.37 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $1,032.35 | 2019-2025 | Orencia |
| Pfizer INC. | $953.92 | 2019-2025 | |
| Abbvie INC. | $635.39 | 2019-2025 | |
| Pacira Therapeutics, INC. | $633.77 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $569.90 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $558.30 | 2019-2025 | Actemra, Rituxan, Gazyva |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kempf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.